Over the next decade, nanotechnology has the potential to influence virtually every aspect of our lives, including our energy, food, water, buildings, and medicines. However, in order to realize this broad potential – robust, cost-effective, regulatory-friendly manufacturing technologies will be required. Through its novel technology platform and expansive intellectual property, Liquidia is poised to be a leader in the development of nanotechnology-based healthcare products and a catalyst for the growth anticipated across this industry.

By leveraging fabrication techniques from the semiconductor industry, Liquidia has the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition. Learn more >


October 8, 2015
Envisia Therapeutics, a Liquidia Spin-out, announces lead product candidate ENV515 achieves primary efficacy endpoint in Phase 2a Glaucoma Clinical Trial     Details

September 30, 2015
Liquidia Technologies and GSK Advance Existing Collaboration; GSK Exercises Option for Inhaled Therapeutics     Details

July 14, 2015
Liquidia Technologies names Robert A. Lippe Chief Operations Officer     Details


October 6, 2015
Fierce Drug Delivery: GSK obtains rights to inhaled nanoparticles made using Liquidia’s PRINT platform     Details

September 30, 2015
TBJ: GSK reaches exclusive deal for technology developed by UNC spinout     Details

April 9, 2015
Vaccine News Daily: Liquidia showcases PRINT vaccine technology at conference     Details

March 15, 2015
Liquidia highlighted as great example of innovation stemming from higher education     Details